Cantor Fitzgerald Adjusts Earnings Forecast for Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) has recently been in the spotlight as analysts at Cantor Fitzgerald released their earnings per share estimates for FY2025. In a note to investors dated January 21st, analyst O. Brayer projected that the biopharmaceutical company will report earnings of $38.93 per share for the year.

Analyst Ratings and Price Targets

Cantor Fitzgerald currently holds a "Neutral" rating on Regeneron Pharmaceuticals, along with a price target of $1,015.00. This forecast is in contrast to the consensus estimate from other analysts, which anticipates that Regeneron's earnings for the current full year will be $37.72 per share.

The stock has been the subject of other reports and analyses as well. For instance, Bank of America reiterated an "underperform" rating with a price target of $565.00 as of December 10th. Meanwhile, Evercore ISI adjusted their target from $1,250.00 to $1,175.00 while maintaining an "outperform" rating on October 24th. Barclays also lowered their price target from $1,080.00 to $1,065.00, assigning an "overweight" rating in their report dated November 1st.

Furthermore, Leerink Partners downgraded Regeneron from a "strong-buy" to a "hold" rating on September 24th, and Oppenheimer reduced their target price from $1,150.00 to $1,000.00 while keeping an "outperform" rating as of November 6th. An analysis of ratings reveals that one analyst has given the stock a sell rating, seven have assigned hold ratings, and fifteen analysts have issued buy ratings. Overall, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $1,015.38 according to MarketBeat.com.

Stock Performance

On Wednesday, shares of Regeneron Pharmaceuticals opened at $687.80. The company boasts a market capitalization of $75.58 billion, with a P/E ratio of 17.02 and a PEG ratio of 1.61. Its beta stands at 0.10, indicating low volatility. The stock has a fifty-day moving average of $735.72 and a two-hundred day moving average of $946.39. Regeneron Pharmaceuticals' debt-to-equity ratio is quite low at 0.09, supported by a quick ratio of 4.46 and a current ratio of 5.28. Over the past year, the stock has reached a low of $666.25 and a high of $1,211.20.

Institutional Investor Activities

Institutional investors are actively managing their positions in Regeneron Pharmaceuticals. For instance, State Street Corp increased its holdings in the third quarter by 1.3%, acquiring an additional 61,277 shares, bringing its total to 4,902,404 shares, valued at approximately $5.15 billion. Another notable move was made by International Assets Investment Management LLC, which boosted its holdings dramatically by 86,013.3%, now owning 880,939 shares worth roughly $926 million.

Additionally, Charles Schwab Investment Management Inc. grew its stake by 1.7% in the third quarter, with a total of 673,261 shares valued at around $707.76 million. The Manufacturers Life Insurance Company and Swiss National Bank also increased their respective positions in the company during the last quarters. Collectively, institutional investors and hedge funds own about 83.31% of Regeneron Pharmaceuticals' stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is dedicated to discovering, inventing, developing, manufacturing, and commercializing medicines for the treatment of a variety of diseases globally. Some of its well-known products include EYLEA, an injection used for treating various eye diseases such as wet age-related macular degeneration and diabetic macular edema.

Regeneron, Earnings, Stocks